Shots:
Addressing a high unmet medical need, PharmaShots had a riveting dialogue exchange with Manojkumar Bupathy from Rocky Mountain Cancer Centers
Manojkumar shared insights from the real-world study that analysed the treatment pattern and clinical outcomes in patients with locally advanced/metastatic urothelial carcinoma
The study reveals that four out of the ten patients received only…
Shots:
Prominent oncology drugs like pembrolizumab and nivolumab were initially approved with weight-based dosing and gradually transitioned to fixed dozing. With the transformation in the dosing model, the average dose amount administered to patients increased dramatically in the Oncology Care Model
Today, at PharmaShots, we have Jennifer Fernandez from The Oncology Network, shedding light on…
Shots:
In the internet-driven world where social media shape opinions and perspectives, it is imperative for companies in the biopharma industry to leverage innovative PR solutions
PR solutions offer significant advantages for biopharma companies that help build their brand values, increase credibility amongst consumers and stakeholders, and much more
With hand-curated offerings designed especially for…
Shots:
There is an average lifetime risk of getting multiple myeloma of about 1 in 103 men and 1 in 131 women in the United States
Treatment of multiple myeloma using fourth-line therapy like teclistamab can induce issues like cytokine release syndrome (CRS) and neurotoxicity
Today, at PharmaShots we have Dr. Robert Rifikin from Rocky…
Shots:
Megestrol, an appetite stimulator is listed as an inappropriate medication based on the American Geriatrics Society (AGS) Beers Criteria and is considered a high-risk medication for elderly people by the Pharmacy Quality Alliance
In a study by the US Oncology Network, the use of megestrol was reviewed and weight gain benefits was evaluated in…
Shots:
Recently, Genmab acquired ProfoundBio in a strategic move to strengthen its position in the ADC space. With this acquisition, Genmab gets ProfoundBio’s novel ADC technology platforms
Today, at PharmaShots, we have Tahi Ahmadi, EVP and Chief Medical Officer at Genmab, sharing insights from the recent acquisition of ProfoundBio by Genmab
With this acquisition, Genmab…
Dedication, a go-getter attitude, and perseverance kept pushing PharmaShots to unlock new achievements now and then. Today, PharmaShots turns six
Started as a news-delivering platform, PharmaShots has evolved over the years as a branding partner to several life sciences companies
We appreciate your unwavering support that kept motivated us and making headway in our journey…
Shots:
Luvelta, an antibody-drug conjugate by Sutro Biopharma is designed to target FRα, expressed in ovarian cancer, developed and manufactured using the company’s proprietary cell-free technology, XpressCF
Today, at PharmaShots, we have Jane Chung, President and CEO at Sutro Biopharma, shedding on the ongoing REFRαME-O1 study evaluating luvelta
Sutro is now enrolling patients for the…
Shots:
Paul A. Frohna, CMO at Endeavor BioMedicines, shed light on two lead assets of the company ENV-101 for Idiopathic Pulmonary Fibrosis and ENV-501 for HER 3 positive solid tumors.
Paul shares insights from the P-IIa results of ENV-101 and talks about the WHISTLE-PF P-II study designed to confirm the efficacy of ENV-101.
While shedding…
Knowledge-packed, informative, and engaging, the Reuters Pharma 2024 event brimmed with enlightening sessions, presentations, and scientific orators shedding light on innovative therapies and unmet needs of the healthcare sector.
Day 1 commenced with keynote speakers shedding light on next-generation customer engagement models, mastering patient-centric metrics, amplifying strategic voice, and expediting equitable access followed by a…

